Description
Product Overview / 商品概要
Lixiana Tablets 60mg (リクシアナ錠60mg)
Generic: Edoxaban Tosilate Hydrate / エドキサバントシル酸塩水和物
Therapeutic Category: Oral FXa Inhibitor / 経口FXa阻害剤
Manufactured by: Daiichi Sankyo Co., Ltd. / 第一三共株式会社
Composition & Specification / 組成・規格
Active Ingredient: Edoxaban Tosilate Hydrate 80.8mg (as Edoxaban 60mg) per tablet / 1錠中 エドキサバントシル酸塩水和物80.8mg(エドキサバンとして60mg)
Additives: D-Mannitol, Partially Alpha-pregelatinized Starch, Crospovidone, Hydroxypropyl Cellulose, Magnesium Stearate, Hypromellose, Titanium Dioxide, Talc, Macrogol 6000, Yellow Ferric Oxide, Carnauba Wax / D-マンニトール、部分アルファー化デンプン、クロスポビドン、ヒドロキシプロピルセルロース、ステアリン酸マグネシウム、ヒプロメロース、酸化チタン、タルク、マクロゴール6000、黄色三二酸化鉄、カルナウバロウ
Appearance: Yellow, oval-shaped film-coated tablet with break line, identification code DSC475, 13.5mm (major axis) × 7.1mm (minor axis), approx. 5.0mm thick, approx. 416mg weight
外観: フィルムコーティング錠(楕円形・割線入)、黄色、識別コードDSC475、13.5mm(長径)×7.1mm(短径)、約5.0mm(厚さ)、約416mg(重さ)
Indications / 効能効果
EN: Prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation; Treatment and prevention of recurrence of venous thromboembolism (deep vein thrombosis and pulmonary embolism); Prevention of thrombus/embolus formation in patients with chronic thromboembolic pulmonary hypertension
JA: 非弁膜症性心房細動患者における虚血性脳卒中及び全身性塞栓症の発症抑制、静脈血栓塞栓症(深部静脈血栓症及び肺血栓塞栓症)の治療及び再発抑制、慢性血栓塞栓性肺高血圧症患者における血栓・塞栓形成の抑制
Dosage and Administration / 用法用量
EN: For prevention of ischemic stroke and systemic embolism in non-valvular atrial fibrillation, treatment and prevention of recurrence of VTE, and prevention of thrombus/embolus formation in CTEPH patients: For patients with body weight over 60kg, administer 60mg of edoxaban once daily orally. Dose may be reduced to 30mg once daily depending on renal function and concomitant medications.
JA: 非弁膜症性心房細動患者における虚血性脳卒中及び全身性塞栓症の発症抑制、静脈血栓塞栓症の治療及び再発抑制、慢性血栓塞栓性肺高血圧症患者における血栓・塞栓形成の抑制:体重60kg超の患者に、エドキサバンとして60mgを1日1回経口投与する。腎機能、併用薬に応じて1日1回30mgに減量する。
Contraindications / 禁忌
EN: Patients with a history of hypersensitivity to any component of this product; Patients with active bleeding; Patients with acute bacterial endocarditis; Patients with renal failure (creatinine clearance <15mL/min) for non-valvular AF, VTE, and CTEPH indications; Patients with hepatic disease associated with coagulopathy for non-valvular AF, VTE, and CTEPH indications
JA: 本剤の成分に対し過敏症の既往歴のある患者、出血している患者、急性細菌性心内膜炎の患者、腎不全(クレアチニンクリアランス15mL/min未満)のある患者(非弁膜症性心房細動・VTE・CTEPH適応)、凝血異常を伴う肝疾患の患者(非弁膜症性心房細動・VTE・CTEPH適応)
Regulatory Information / 規制情報
Approval No.: 22600AMX01308
Sales Started: December 2014 / 2014年12月
Classification Code: 873339
Storage: Store at room temperature / 室温保存
Shelf Life: 3 years / 3年
Packaging / 包装
Main Package (for sale): 100 tablets (10 tablets x 10) / 100錠(10錠×10)
Other Available Packages (by special order): 100 tablets (plastic bottle, bulk), 100 tablets (PTP: 10 tablets x 10), 140 tablets (PTP: 14 tablets x 10)
Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Reviews
There are no reviews yet.